New combo therapy aims to outsmart leukemia with less poison
NCT ID NCT07643103
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamicin, venetoclax, blinatumomab) and possibly CAR-T cell therapy. The goal is to achieve a deep remission with fewer side effects. The study will enroll 32 participants and track how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inotuzumab Ozogamicin, Venetoclax, Blinatumomab, and CD19 CAR-T cells
What this could lead to
If successful, this approach could offer a more effective and less toxic first-line treatment for Ph-negative B-ALL, potentially reducing the need for intensive chemotherapy.
What could go wrong
This is a small, early-phase (phase 2) trial with only 32 participants. The combination may cause unexpected side effects, and results may not apply to all patients. Long-term benefits are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH- ACUTE LYMPHOBLASTIC LEUKEMIA (PH-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••